Biocon's New Vistas ; After Changing Its Focus From Enzymes to Biopharma, India's Best- Known Biotech Company Wants to Transform Itself Into a Truly Global Company.

Summary

---

For almost the whole of July and August, Biocon Founder Kiran Mazumdar-Shaw has been on a trip many trips, actually racking up frequent-flier miles across the US and Europe to meet customers, partners and regulators. The trigger: Biocon 's landmark deal signed June 29 with US generics major Mylan Inc.

The Mylan deal is a key component of her plan to turn India 's best-known biotech firm into a global player, a research-based powerhouse turning out innovative drugs and biosimilars (the generics of the biotech world) and give Biocon a global footprint.

See the full content of this document

Extract

---

Biocon's New Vistas ; After Changing Its Focus From Enzymes to Biopharma, India's Best- Known Biotech Company Wants to Transform Itself Into a Truly Global Company.

"I want Biocon to be a leading innovator from India" she said, back home after the last flight. In fact, Mazumdar-Shaw, who became India 's richest woman when Biocon listed in 2004, has her eyes set on a place among the world 's top 10 biotech firms.

Today, Biocon, which began as an enzymes maker, gets over 80 per cent of its revenues from traditional generics and biosimilars....

See the full content of this document

---